Plain-English translation of NCT05531565 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called as a potential treatment for cutaneous lupus erythematosus—a type of lupus that primarily affects the skin. Some participants will receive injections, while others will receive placebo (a dummy injection with no medication), to see if the medication helps reduce skin symptoms and disease activity. The study will involve about 450 people and is being run in two parts to first test whether the medication works, then confirm those results in a larger group.
Many people with cutaneous lupus erythematosus don't respond well to the standard antimalarial medications (like hydroxychloroquine), or they can't tolerate those drugs because of side effects. This medication targets a specific part of the immune system involved in lupus, and researchers hope it may offer a new option for people who need better skin disease control.
You will receive injections under the skin approximately every 4 weeks for up to one year, with a few extra doses in the first couple of weeks. Half of participants will receive the real medication and half will receive placebo (neither you nor the study team will know which you're getting). You will have regular study visits where your skin will be examined and assessed, and you may have blood tests. The study is divided into two phases: an initial phase to test whether the medication works, followed by a longer phase if the early results look promising.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States